Deciphera Pharmaceuticals soared more than 47% on Monday, thanks to encouraging updated data from its ongoing Phase 1 clinical trial of DCC-2618 in patients with gastrointestinal stromal tumors (GIST) that were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday.
Original Article: DCPH Soars On ASCO Data, AVXL Braces For Busy Year, GHDX In Good Health